Assessment of Risk Factors for Appropriate ICD (Implantable Cardioverter-defibrillator) Intervention in Patients With Ischemic Cardiomyopathy (PARCADIA)
Prospective Assessment of Risk Factors for Appropriate ICD Intervention in Patients With Ischemic Cardiomyopathy
Sponsor: Biotronik SE & Co. KG
A NA clinical study on Cardiomyopathy Ischemic and ICD, this trial is completed. The trial is conducted by Biotronik SE & Co. KG and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Oct 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
May 2020 — Oct 2020 [monthly]
Active Not Recruiting NA
▶ Show 1 earlier version
-
Aug 2019 — May 2020 [monthly]
Active Not Recruiting NA
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biotronik SE & Co. KG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.